Genocea Biosciences (NASDAQ:GNCA) Research Coverage Started at Leerink Swann

Leerink Swann started coverage on shares of Genocea Biosciences (NASDAQ:GNCA) in a research note released on Friday morning, The Fly reports. The firm issued an outperform rating on the biotechnology company’s stock.

A number of other equities analysts also recently commented on GNCA. ValuEngine raised shares of Genocea Biosciences from a hold rating to a buy rating in a report on Friday, November 1st. Needham & Company LLC reaffirmed a buy rating and set a $10.00 price objective on shares of Genocea Biosciences in a report on Thursday, October 24th. Zacks Investment Research downgraded shares of Genocea Biosciences from a buy rating to a hold rating in a report on Tuesday, October 29th. Finally, HC Wainwright reaffirmed a buy rating on shares of Genocea Biosciences in a report on Monday, November 11th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Genocea Biosciences currently has a consensus rating of Buy and a consensus target price of $12.94.

NASDAQ GNCA traded up $0.03 during midday trading on Friday, hitting $2.26. The company had a trading volume of 625 shares, compared to its average volume of 135,046. The company has a quick ratio of 4.33, a current ratio of 4.33 and a debt-to-equity ratio of 0.45. The stock has a market cap of $58.83 million, a price-to-earnings ratio of -0.61 and a beta of 2.43. The firm has a fifty day simple moving average of $2.54 and a two-hundred day simple moving average of $3.19. Genocea Biosciences has a fifty-two week low of $1.99 and a fifty-two week high of $11.28.

Genocea Biosciences (NASDAQ:GNCA) last released its quarterly earnings data on Thursday, October 24th. The biotechnology company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.17. As a group, equities analysts predict that Genocea Biosciences will post -1.78 earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in the stock. Morgan Stanley bought a new position in Genocea Biosciences during the 2nd quarter valued at about $26,000. Cubist Systematic Strategies LLC bought a new position in Genocea Biosciences during the 2nd quarter valued at about $40,000. Wedbush Securities Inc. bought a new position in Genocea Biosciences during the 2nd quarter valued at about $43,000. Citadel Advisors LLC bought a new position in Genocea Biosciences during the 2nd quarter valued at about $68,000. Finally, D. E. Shaw & Co. Inc. bought a new position in Genocea Biosciences during the 2nd quarter valued at about $84,000. 56.50% of the stock is owned by hedge funds and other institutional investors.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.

Read More: Dividend

The Fly

Analyst Recommendations for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.